149 related articles for article (PubMed ID: 38393945)
1. Structural insights into IL-6 signaling inhibition by therapeutic antibodies.
Wang M; Chen L; He J; Xia W; Ye Z; She J
Cell Rep; 2024 Mar; 43(3):113819. PubMed ID: 38393945
[TBL] [Abstract][Full Text] [Related]
2. What do we know about IL-6 in COVID-19 so far?
Jiang J; Wang J; Yao L; Lai S; Zhang X
Biophys Rep; 2021 Jun; 7(3):193-206. PubMed ID: 37287491
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L; Assi R; Evrenoglou T; Buckley BS; Henschke N; Probyn K; Riveros C; Davidson M; Graña C; Bonnet H; Jarde A; Ávila C; Nejstgaard CH; Menon S; Ferrand G; Kapp P; Breuer C; Schmucker C; Sguassero Y; Nguyen TV; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Chaimani A; Boutron I
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013881. PubMed ID: 37260086
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
5. Characterization of HZ0412a, a novel potent humanized anti-IL-6 receptor antibody that blocks IL-6R binding to gp130.
Han J; Liu X; Xu Y; Wang Q; Li L; Du K; Li C; Liu H; Chen Y; Huang J
Antib Ther; 2023 Apr; 6(2):119-126. PubMed ID: 37324549
[TBL] [Abstract][Full Text] [Related]
6. IL-6-induced response of human osteoblasts from patients with rheumatoid arthritis after inhibition of the signaling pathway.
Sellin ML; Klinder A; Bergschmidt P; Bader R; Jonitz-Heincke A
Clin Exp Med; 2023 Nov; 23(7):3479-3499. PubMed ID: 37280473
[TBL] [Abstract][Full Text] [Related]
7. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
[TBL] [Abstract][Full Text] [Related]
8. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
9. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19.
Parums DV
Med Sci Monit; 2021 Jul; 27():e933973. PubMed ID: 34276042
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
[TBL] [Abstract][Full Text] [Related]
13. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis.
Maioli G; Caporali R; Favalli EG
Expert Opin Drug Discov; 2022 Aug; 17(8):799-813. PubMed ID: 35757853
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6: A Masterplayer in the Cytokine Network.
Uciechowski P; Dempke WCM
Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
[TBL] [Abstract][Full Text] [Related]
16. Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters.
Xu C; Rafique A; Potocky T; Paccaly A; Nolain P; Lu Q; Iglesias-Rodriguez M; St John G; Nivens MC; Kanamaluru V; Fairhurst J; Ishii T; Maldonado R; Choy E; Emery P
J Clin Pharmacol; 2021 May; 61(5):714-724. PubMed ID: 33314148
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
Cronstein BN
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
[TBL] [Abstract][Full Text] [Related]
18. IL-6: from arthritis to CAR-T-cell therapy and COVID-19.
Kishimoto T
Int Immunol; 2021 Sep; 33(10):515-519. PubMed ID: 33715009
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
[TBL] [Abstract][Full Text] [Related]
20. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.
Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A
Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
